Adults with Autosomal Recessive Congenital Ichthyosis are Needed for a Research Study of KB105, a Topical Gene Therapy
Adults with Autosomal Recessive Congenital Ichthyosis are Needed for a Research Study of KB105, a Topical Gene Therapy
Krystal Biotech is currently conducting a Phase I/II research study to evaluate the safety and effectiveness of an investigational topical gene therapy, KB105, for people with Autosomal Recessive Congenital Ichthyosis, or ARCI. The TGM1 study is being conducted to determine if topical KB105 can safely and effectively promote improvement in disease severity of ARCI subjects and to assess change from baseline in Investigator Global Assessments. Adults that have the lamellar ichthyosis form of ARCI may be eligible for participation. Participants are enrolled upon obtaining consent and meeting entry criteria. Four skin areas (Target Areas) are selected per subject; three will receive KB105 and one will receive placebo. Throughout the study, the Target Areas will undergo safety and efficacy analyses. Subjects will be on-trial for approximately 3 months, followed by a 1-year visit.
For more information about the study please visit our clinicaltrials.gov link (https://clinicaltrials.gov/ct2/show/NCT04047732) or contact us by email at patientadvocacy@krystalbio.com.
